Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308979 · ClinicalTrials.gov registry record · Phase 4
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
A Phase 4 study of Overactive Bladder and Overactive Bladder Syndrome, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT05308979: Completed Phase 4 study of Overactive Bladder and Overactive Bladder Syndrome, sponsored by University of California, Irvine.
NCT05308979 is a Phase 4 study of Overactive Bladder and Overactive Bladder Syndrome that has completed, run by University of California, Irvine. The registered enrollment target is 116 participants, below the 205-participant average among 46 other Overactive Bladder trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05308979, a Phase 4 study of Overactive Bladder and Overactive Bladder Syndrome, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
Primary Outcome
Participants will be asked to Overactive Bladder Questionnaire Long Form prior to receiving the Botox procedure. The OAB-Q LF symptom severity sub-scale score will be compared prior to procedure and again to score at 3 weeks after procedure. The OAB-q Symptom Severity Score will be computed at baseline and 3 weeks (and 3 months) using the standard scoring algorithm. Minimum value of symptom severity subscale is 8, maximum is 48. A higher score means worse symptoms. A lower score means less symp
Conditions Studied
Interventions
- DRUG OnabotulinumtoxinA 100 UNT [Botox]
Study Locations (1)
California
- University of California Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 4 |
What the finished NCT05308979 record still lists
NCT05308979 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 205-participant average among 46 other Overactive Bladder trials with a reported enrollment target (43% lower).
The record links to 7 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which OnabotulinumtoxinA 100 UNT [Botox] is the first listed.
NCT05308979 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05308979 about?
NCT05308979 is a clinical study titled "Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial". Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
What is the current status of trial NCT05308979?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2022-05-01. Estimated completion is 2024-03-31.
What conditions does trial NCT05308979 study?
This clinical trial studies the following conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urge Incontinence.
What interventions are being tested in trial NCT05308979?
The interventions under investigation include: OnabotulinumtoxinA 100 UNT [Botox] (DRUG).
Who is sponsoring clinical trial NCT05308979?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05308979 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05308979's enrollment target sits among peer trials
116 22nd of 46 higher than 25 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
RECRUITING · Phase 4
-
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI